Antidepressants for Dementia Prevention? Antidepressants for Dementia Prevention?
The SSRI escitalopram appears to lower amyloid-beta levels in cerebrospinal fluid of cognitively normal older adults, suggesting a potential role for these drugs in preventing Alzheimer's disease.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - September 18, 2020 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news

MGH scientists identify PET tracer for Alzheimer's
Massachusetts General Hospital (MGH) scientists have developed a molecular...Read more on AuntMinnie.comRelated Reading: MRI links brain iron to Alzheimer's decline PET tracer could more precisely diagnose Alzheimer's PET links amyloid to cognitive decline in A4 study PET shows connection with widowhood, Alzheimer's decline DTI-MRI ties lack of fitness to cognitive decline (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2020 Category: Radiology Source Type: news

Covid-19 was the 24th most common cause of death in England last month
Official data shows more people died of Alzheimer's, heart disease, cancerous lung, colon or rectum tumours, and the flu than they did of the coronavirus in England and Wales. (Source: the Mail online | Health)
Source: the Mail online | Health - September 18, 2020 Category: Consumer Health News Source Type: news

New Research Suggests Clinical Laboratory Blood Tests Could Fill A Void in Alzheimer ’s Disease Diagnoses
Studies presented at the Alzheimer’s Association International Conference point to the p-tau217 protein as an especially useful biomarker Researchers disclosed a potentially useful biomarker for Alzheimer’s Disease at a major conference this summer. The good news for clinical laboratories is that the biomarker is found in blood. If further research confirms these early findings, medical […] The post New Research Suggests Clinical Laboratory Blood Tests Could Fill A Void in Alzheimer’s Disease Diagnoses first appeared on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - September 18, 2020 Category: Laboratory Medicine Authors: Jude Tags: Instruments & Equipment Laboratory Instruments & Laboratory Equipment Laboratory Management and Operations Laboratory News Laboratory Operations Laboratory Pathology Management & Operations AAIC Alzheimer’s Association International Conf Source Type: news

new alteration in the brain of people with Alzheimer's discovered
(Spanish National Research Council (CSIC)) New research led by Spanish scientists suggest that the altered glycosylation could determine that the Amyloid Precursor Protein (APP) is processed by the amyloidogenic (pathological) pathway, giving rise to the production of the beta-amyloid, a small protein with a tendency to cluster forming the amyloid plaques characteristic of Alzheimer's disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 18, 2020 Category: International Medicine & Public Health Source Type: news

PET/MRI boosts cancer detection
PET/MRI helps clinicians stage cancer treatment as well as PET/CT -- and finds...Read more on AuntMinnie.comRelated Reading: PET/MRI ups lesion detection by 15% for some cancers SNMMI 2020: PET/MRI finds location of chronic pain in patients SNMMI 2020: PET/MRI combo tracks osteoarthritis progression PET, MRI uncover women's predisposition to Alzheimer's PET/MRI shows inflammation link to mitral valve prolapse (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 17, 2020 Category: Radiology Source Type: news

Another Gene Linked to Alzheimer's Risk
Title: Another Gene Linked to Alzheimer's RiskCategory: Health NewsCreated: 9/16/2020 12:00:00 AMLast Editorial Review: 9/17/2020 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - September 17, 2020 Category: Geriatrics Source Type: news

Alzheimer's Disease Clinical Trial Participation Motivations Alzheimer's Disease Clinical Trial Participation Motivations
What motivates individuals to participate in, and stay involved with, Alzheimer's disease clinical trials?The Gerontologist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 17, 2020 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Imaging probe to visualize Alzheimer's disease-related gamma-secretase in the brain
(Massachusetts General Hospital) Scientists have developed a molecular imaging probe to reveal Alzheimer's-relatedγ-secretase in rodents and macaques with translational potentials in humans (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 17, 2020 Category: International Medicine & Public Health Source Type: news

New Research Links Another Gene to Alzheimer's Risk
WEDNESDAY, Sept. 16, 2020 -- A genetic variant in some people may be associated with mental decline that can't be explained by deposits of two proteins linked with Alzheimer's disease, researchers say. They said their findings could lead to new... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 16, 2020 Category: General Medicine Source Type: news

Common Apnea Treatment Tied to Lower Dementia Risk Common Apnea Treatment Tied to Lower Dementia Risk
Treatment of obstructive sleep apnea with positive airway pressure was associated with a lower odds of incident Alzheimer's disease and other dementia in a large retrospective cohort study.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 16, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

PET helps diagnose treatable form of dementia
PET imaging could be a useful tool for diagnosis and treatment of idiopathic...Read more on AuntMinnie.comRelated Reading: FDG levels show link between Alzheimer's, Down syndrome SNMMI 2020: Image of the Year scans reveal 'super-agers' New tau PET tracer better targets source of Alzheimer's New PET technique visualizes early Alzheimer's disease PET tracer could more precisely diagnose Alzheimer's (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 16, 2020 Category: Radiology Source Type: news

Mayo Clinic Q and A: Neurologic function and COVID-19
DEAR MAYO CLINIC: My family has a history of neurologic disease. My grandfather died from a stroke. An uncle was diagnosed with early-onset Alzheimer's disease at 40, and my brother recently was diagnosed with an aneurysm. I'm wondering if our family is at greater risk for COVID-19? Are there any neurologic symptoms we should be [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 16, 2020 Category: Databases & Libraries Source Type: news

Decoding the genetics that drive disease
(University of South Australia) From Alzheimer's to obesity, life can change dramatically if you discover you have a genetic risk of disease. Now, a new study from the Australian Centre for Precision Health, University of South Australia is challenging these predispositions, showing that some of the genes traditionally labelled as 'bad' are not always what they seem. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 15, 2020 Category: Biology Source Type: news

Seattle Alzheimer ’s drug developer Athira Pharma aims to raise $170M in IPO
Athira Pharma will try to raise upwards of $170 million in its initial public offering this year, according to documents filed with the U.S. Securities and Exchange Commission on Monday. On Aug. 26, the company filed that it was planning an IPO later this year. In Monday’s filing the company said it will offer 10 million shares of common stock at a price between $15 and $17 per share. Potentially another 1.5 million shares will be offered at those prices. The IPO would suppor t the company’s… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 14, 2020 Category: Biotechnology Authors: Megan Campbell Source Type: news

Seattle Alzheimer ’s drug developer Athira Pharma aims to raise $170M in IPO
Athira Pharma will try to raise upwards of $170 million in its initial public offering this year, according to documents filed with the U.S. Securities and Exchange Commission on Monday. On Aug. 26, the company filed that it was planning an IPO later this year. In Monday’s filing the company said it will offer 10 million shares of common stock at a price between $15 and $17 per share. Potentially another 1.5 million shares will be offered at those prices. The IPO would suppor t the company’s… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 14, 2020 Category: Pharmaceuticals Authors: Megan Campbell Source Type: news

NIH to fund PET imaging for Latino Alzheimer's study
The U.S. National Institutes of Health (NIH) has provided additional funding...Read more on AuntMinnie.comRelated Reading: MRI-trained CAD identifies cognitive impairment FDG levels show link between Alzheimer's, Down syndrome New tau PET tracer better targets source of Alzheimer's New PET technique visualizes early Alzheimer's disease PET tracer could more precisely diagnose Alzheimer's (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 14, 2020 Category: Radiology Source Type: news

Omega-3s to Prevent Alzheimer's: Who Benefits? Omega-3s to Prevent Alzheimer's: Who Benefits?
Drs Richard Isaacson and Hussein Yassine discuss omega-3 fatty acid supplementation for the prevention of Alzheimer ’ s disease.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 14, 2020 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news

NIH augments large scale study of Alzheimer ’s disease biomarkers
HABLE study prioritizes brain imaging and biomarker research among Mexican Americans. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - September 14, 2020 Category: American Health Source Type: news

Cassava Sciences Announces Positive Results In Phase 2 Trial Of New Alzheimer ’s Drug
The drug, sumifilam, targets a new protein in Alzheimer ’s disease called Filamen A. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 14, 2020 Category: Pharmaceuticals Authors: Leah Rosenbaum, Forbes Staff Tags: Innovation /innovation Healthcare /healthcare Science /science Editors' Pick editors-pick Source Type: news

Is Rural Appalachia a Hotspot for Alzheimer's?
Title: Is Rural Appalachia a Hotspot for Alzheimer's?Category: Health NewsCreated: 9/11/2020 12:00:00 AMLast Editorial Review: 9/14/2020 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - September 14, 2020 Category: Geriatrics Source Type: news

Older people with early, asymptomatic Alzheimer's at risk of falls
(Washington University School of Medicine) Older people without cognitive problems who experience a fall may have undetected neurodegeneration in their brains that puts them at high risk of developing Alzheimer's dementia, according to a study from Washington University School of Medicine in St. Louis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2020 Category: International Medicine & Public Health Source Type: news

Researchers receive $45 million grant to study health disparities in Alzheimer's disease
(University of North Texas Health Science Center) The 5-year research grant, awarded to Sid O'Bryant, PhD, Professor and Executive Director of the Institute for Translational Research, and Leigh Johnson, PhD, Associate Professor and Associate Director, is the largest research award ever received by The University of North Texas Health Science Center at Fort Worth. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2020 Category: International Medicine & Public Health Source Type: news

IU researchers receive grant to deploy collaborative dementia care model across Indiana
(Indiana University School of Medicine) Supported by a $1.3 million grant from the U.S. Administration for Community Living, Department of Health and Human Services, Indiana University School of Medicine and its partners have launched a 36-month venture to enhance, strengthen and expand supports for people with Alzheimer's Disease and Related Dementias (ADRD) and their caregivers in 34 Indiana counties. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 14, 2020 Category: International Medicine & Public Health Source Type: news

NIH augments large scale study of Alzheimer's disease biomarkers
(NIH/National Institute on Aging) To better understand the prevalence, progression, and clinical impact of Alzheimer's among Mexican Americans, NIH has added funding for more biomarker measures to the HABLE Study. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 14, 2020 Category: International Medicine & Public Health Source Type: news

Farlong Pharmaceutical Donates a Portion of Sales Throughout the Month...
To spread awareness about World Alzheimer's Month, Farlong is donating 10% of sales from Lifeflower® Breviscapine throughout September to the Alzheimer’s Foundation of America(PRWeb September 14, 2020)Read the full story at https://www.prweb.com/releases/farlong_pharmaceutical_donates_a_portion_of_sales_throughout_the_month_of_september_to_the_alzheimers_foundation_of_america/prweb17389454.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 14, 2020 Category: Pharmaceuticals Source Type: news

The what and the who of Linda
A psychic once told me that it was almost as if I had appeared fully formed on earth at the age of 10 – rather like Mr Bean – with no history or family to speak of. With a statement like that I might have felt it incumbent upon me to explain why the age of 10 was so significant in my life, and whilst it surely would have been interesting to you; personally, I’m much more interested in the present.  As Leslie Poles Hartley once said “the past is a foreign country, they do things differently there“. People, I believe, are often tarred with two brushes.  That of ‘WHAT’ they...
Source: The Hysterectomy Association - September 13, 2020 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Creativity my story Source Type: news

Dementia symptoms: The number of years it can take for a person to develop symptoms
DEMENTIA frequently occurs in people aged 65 and above, with the most common form of the disease being Alzheimer's disease. Yet, it can take a long time before symptoms begin to appear. (Source: Daily Express - Health)
Source: Daily Express - Health - September 12, 2020 Category: Consumer Health News Source Type: news

Is Rural Appalachia a Hotspot for Alzheimer's?
FRIDAY, Sept. 11, 2020 -- Alzheimer's disease is more common in rural Appalachian areas of Ohio than in other rural parts of the state, new research shows. For the study, the investigators analyzed 11 years of Medicare data, ending in 2017, and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 11, 2020 Category: General Medicine Source Type: news

New data further reinforce Roche ’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
Basel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analys is from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee...
Source: Roche Media News - September 11, 2020 Category: Pharmaceuticals Source Type: news

New data further reinforce Roche ’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
Basel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analys is from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee...
Source: Roche Investor Update - September 11, 2020 Category: Pharmaceuticals Source Type: news

UAB named an exploratory Alzheimer ’s Disease Research Center
UAB has been selected as an exploratory center for Alzheimer's disease research. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 10, 2020 Category: Biotechnology Authors: Tyler Patchen Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Media News - September 10, 2020 Category: Pharmaceuticals Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Investor Update - September 10, 2020 Category: Pharmaceuticals Source Type: news

Concussion discovery reveals dire, unknown effect of even mild brain injuries
(University of Virginia Health System) Even mild concussions cause severe and long-lasting impairments in the brain's ability to clean itself, and this may seed it for Alzheimer's, dementia and other neurodegenerative problems. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

NIH expands nation's Alzheimer's and related dementias research capacity
(NIH/National Institute on Aging) NIH has funded four new exploratory centers to broaden current Alzheimer's disease research initiatives with underrepresented populations. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 10, 2020 Category: International Medicine & Public Health Source Type: news

Failure of Omega-3s to Prevent, Slow Alzheimer's Explained? Failure of Omega-3s to Prevent, Slow Alzheimer's Explained?
Supplementation with the docosahexaenoic acid omega-3 fatty acid causes substantial increases in plasma concentrations, but increases in the brain are much less pronounced.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - September 9, 2020 Category: Psychiatry Tags: Psychiatry News Source Type: news

Depression Can Deepen Over Time for Alzheimer ’ s Caregivers
(Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - September 9, 2020 Category: Psychiatry Tags: Neurology, Nursing, Psychiatry, Geriatrics, News, Source Type: news

Depression Can Deepen Over Time for Alzheimer's Caregivers
WEDNESDAY, Sept. 9, 2020 -- Add a heightened risk for depression to the list of challenges facing the caregivers of loved ones who have Alzheimer's disease. A new study found that older adults caring for spouses newly diagnosed with Alzheimer's had... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 9, 2020 Category: General Medicine Source Type: news

Depression Can Deepen Over Time for Alzheimer's Caregivers
Title: Depression Can Deepen Over Time for Alzheimer's CaregiversCategory: Health NewsCreated: 9/9/2020 12:00:00 AMLast Editorial Review: 9/9/2020 12:00:00 AM (Source: MedicineNet Depression General)
Source: MedicineNet Depression General - September 9, 2020 Category: Psychiatry Source Type: news

Failure of Omega-3s to Prevent, Slow Alzheimer's
Explained? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 9, 2020 Category: General Medicine Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Media News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Investor Update - September 9, 2020 Category: Pharmaceuticals Source Type: news

Albert Einstein College of Medicine receives $16 million NIH grant to study cellular process linked to Alzheimer's disease
(Albert Einstein College of Medicine) Researchers at Albert Einstein College of Medicine, led by Ana Maria Cuervo, M.D., Ph.D., co-director of the Institute for Aging Research, have received a five-year, $16 million grant from the NIH to determine how autophagy, a cellular recycling process, is related to the development of Alzheimer's disease and related dementias. The multidisciplinary team working to untangle this puzzle includes experts in the biology of aging, neurodegeneration, metabolism, immunology, stem cells, drug development, and advanced imaging. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 9, 2020 Category: International Medicine & Public Health Source Type: news

Albert Einstein College of Medicine Receives $16 Million NIH Grant to Study Cellular Process Linked to Alzheimer ’s Disease
September 8, 2020—(BRONX, NY)—Age is the most significant risk factor for Alzheimer’s disease. In the United States, approximately 1 in 10 people over the age of 65 have the disease, and the odds increase to nearly 1 in 3 for those over 85. However, the mechanisms by which aging increases risk are unknown. (Source: Einstein News)
Source: Einstein News - September 8, 2020 Category: Universities & Medical Training Source Type: news

A Multiomics Approach to Heterogeneity in Alzheimer's Disease A Multiomics Approach to Heterogeneity in Alzheimer's Disease
This review highlights three omics techniques--neuroimaging-based subtypes, metabolomic panels, and polygenic risk scores--and their application as diagnostic tools in Alzheimer disease.Brain (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 8, 2020 Category: Radiology Tags: Neurology & Neurosurgery Journal Article Source Type: news

Linking calorie restriction, body temperature and healthspan
(Scripps Research Institute) Cutting calories significantly may not be an easy task for most, but it's tied to a host of health benefits ranging from longer lifespan to a much lower chance of developing cancer, heart disease, diabetes and neurodegenerative conditions such as Alzheimer's. A new study from teams led by Scripps Research Professors Bruno Conti, PhD , and Gary Siuzdak, PhD , illuminates the critical role that body temperature plays in realizing these diet-induced health benefits. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 8, 2020 Category: Biology Source Type: news

Mild cognitive impairment in retired professional football players with a history of mild traumatic brain injury: a pilot investigation - Didehbani N, Fields LM, Wilmoth K, LoBue C, Hart J, Cullum CM.
BACKGROUND: Traumatic brain injury (TBI) is a known risk factor for neurodegenerative dementias such as Alzheimer disease (AD); however, the potential risk of mild cases of TBI, such as concussions, remains unclear. OBJECTIVE: To explore whether a smal... (Source: SafetyLit)
Source: SafetyLit - September 7, 2020 Category: International Medicine & Public Health Tags: Recreational and Sports Issues Source Type: news

Dementia: Six simple ways to make life easier for a loved one with the brain condition
DEMENTIA is a degenerative illness, and September is World Alzheimer's' Month. Bringing attention to the brain condition, here are six simple ways to make life a little bit easier when attending to the needs of a loved one who has the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - September 6, 2020 Category: Consumer Health News Source Type: news

Dementia warning - the mood changes that could be an early sign of Alzheimer’s
DEMENTIA symptoms include difficulty concentrating, memory loss, and having slower thoughts. But you could also be at risk of Alzheimer's disease if you develop subtle mood changes. When should you consider speaking to a doctor about Alzheimer's disease symptoms? (Source: Daily Express - Health)
Source: Daily Express - Health - September 4, 2020 Category: Consumer Health News Source Type: news